Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alkermes (ALKS)

Alkermes names Joshua Reed as CFO, effective September 15, 2025

Neutral Impact 4 of 5 leadership Written later

Alkermes plc appointed Joshua Reed as Senior Vice President and Chief Financial Officer, effective September 15, 2025, replacing an interim arrangement in which Blair C. Jackson performed the principal financial officer role. Reed brings more than 30 years of financial leadership experience, including prior CFO roles at Omega Therapeutics and Aldeyra Therapeutics, and his compensation includes a $615,000 base salary and a $3.5 million new hire equity grant.

Key points

  • Joshua Reed becomes CFO effective September 15, 2025, and will report to CEO Richard Pops
  • Initial base salary of $615,000 with a target annual cash incentive of 50% of base salary, pro-rated for 2025
  • New hire equity grant with an aggregate target value of $3.5 million, about 67% stock options and 33% restricted stock units
  • Change-in-control severance includes a lump sum of one and one-half times base salary plus average incentive pay

The filing

CompanyAlkermes (ALKS)
Form8-K, current report
Filed with the SECSep 12, 2025, 9:09 AM ET
Accession number0001193125-25-201840

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 12, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.